MLN-3897

TargetMol
Product Code: TAR-T28072
Supplier: TargetMol
CodeSizePrice
TAR-T28072-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28072-5mg5mg£431.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28072-10mg10mg£613.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28072-25mg25mg£997.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28072-50mg50mg£1,458.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28072-100mg100mg£2,155.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
MLN-3897 is a C-C Motif Chemokine Receptor 1 (CCR1) antagonist. MLN3897 abrogates its effects by inhibiting Akt signaling. MLN3897 abrogates MM cell-to-OC adhesion, thereby inhibiting MM cell survival and proliferation.
CAS:
1010731-97-1
Formula:
C32H39ClN2O3
Molecular Weight:
535.13
Pathway:
Microbiology/Virology|Immunology/Inflammation
Purity:
0.98
SMILES:
CC(C)(O)c1ccc2OCC3=C(C=CCN3)C(=C/CCN3CC[C@](O)(c4ccc(Cl)cc4)C(C)(C)C3)c2c1
Target:
CCR

References

1. Pusalkar S, Plesescu M, Milton M, Balani SK, Chowdhury S, Prakash S. Metabolism, Excretion and Pharmacokinetics of MLN3897, a CCR1 Antagonist, in Humans. Drug Metab Lett. 2016;10(1):22-37. PubMed PMID: 26031460. 2. Vergunst CE, Gerlag DM, von Moltke L, Karol M, Wyant T, Chi X, Matzkin E, Leach T, Tak PP. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum. 2009 Dec;60(12):3572-81. doi: 10.1002/art.24978. PubMed PMID: 19950299. 3. Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist. J Pharmacol Exp Ther. 2010 Feb;332(2):562-8. doi: 10.1124/jpet.109.161893. PubMed PMID: 19889796. 4. Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood. 2007 Nov 15;110(10):3744-52. PubMed PMID: 17715391; PubMed Central PMCID: PMC2077320.